Document:

Exhibit 10.1

 

UNIT PURCHASE AGREEMENT

 

UNIT PURCHASE AGREEMENT
(this “Agreement”) made as of the date set forth on the signature page hereof between Aethlon Medical, Inc., a Nevada
corporation (the “Company”), and the subscriber(s) identified on Exhibit A annexed hereto (the “Subscriber”).

 

W I T N E S S E T H:

 

WHEREAS, the Company
is conducting a private offering (the “Offering”) consisting of up to a maximum of 160 units (the “Units”),
each Unit consisting of (a) one hundred thousand (100,000) shares of the Company’s common stock par value $0.001 per share
(the “Common Stock”) at a purchase price of $0.125 per share and (b) a five-year warrant (collectively, the “Warrants”
and together with the Units and Common Stock, the “Securities”) to purchase fifty thousand (50,000) shares of Common
Stock of the Company at an exercise price equal to $0.22 per share, subject to equitable adjustment thereunder (the “Exercise
Price”) at a negotiated price of $12,500 per Unit (the “Unit Purchase Price”);

 

WHEREAS, the Company
has retained __________________ to act as its placement agent in connection with the sale of the Units pursuant to this Agreement
(the “Placement Agent”);

 

WHEREAS, the Offering
is on a “best efforts, all-or-none” basis to attain the minimum offering amount of $200,000 purchase price for the
Units (the “Minimum Offering”), and on a “reasonable efforts” basis as to the remaining Units to be sold
up to the maximum offering amount of $2,000,000 purchase price for the Units (the “Maximum Offering”), to a limited
number of “accredited investors” (as that term is defined by Rule 501(a) of Regulation D (“Regulation D”)
promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the
“Securities Act”);

 

WHEREAS, the Company
and each Subscriber is executing and delivering this agreement in reliance upon the exemption from securities registration afforded
by Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated by the SEC under the Securities Act;

 

WHEREAS the subscription
for the Securities will be made in accordance with and subject to the terms and conditions of this Subscription Agreement and the
Company’s Confidential Private Placement Memorandum dated October 10, 2013, together with all amendments thereof and supplements
and exhibits thereto and as such may be amended from time to time (the “Memorandum”); and

 

WHEREAS, the Subscriber
desires to purchase such number of Units as set forth on the signature page hereof on the terms and conditions hereinafter set
forth.

 

    	1

    	 

    

 

NOW, THEREFORE, in consideration
of the premises and the mutual representations and covenants hereinafter set forth, the parties hereto do hereby agree as follows:

 

		I.	SUBSCRIPTION FOR SECURITIES

 

1.1   
Subject to the terms and conditions hereinafter set forth and as set forth in the Memorandum, the Subscriber hereby subscribes
for and agrees to purchase from the Company, and the Company subject to its rights to accept or reject this subscription, agrees
to sell to the Subscriber, such number of Units for the aggregate purchase price as is set forth on the signature page hereof.
The purchase price is payable by wire transfer, to be held in escrow until the conditions to closing are achieved, to Signature
Bank, the escrow agent (the “Escrow Agent”) as follows:

 

Bank:

ABA Number:

Account #:

Account Name:

Swift Code:

 

1.2   
The Subscriber understands acknowledges and agrees that, except as otherwise set forth herein or otherwise required by law,
that once irrevocable, the Subscriber is not entitled to cancel, terminate or revoke this Agreement or any agreements of the Subscriber
hereunder and that this Agreement and such other agreements shall survive the death or disability of the Subscriber and shall be
binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal representatives
and permitted assigns. If the Subscriber is more than one person, the obligations of the Subscriber hereunder shall be joint and
several and the agreements, representations, warranties and acknowledgments herein contained shall be deemed to be made by and
be binding upon each such person and his/her heirs, executors, administrators, successors, legal representatives and permitted
assigns.

 

II.REPRESENTATIONS BY SUBSCRIBER

 

Each Subscriber hereby
severally, and not jointly, represents and warrants to the Company that each such Subscriber’s representations in the Subscription
Agreement, in the form attached as Exhibit A to the Memorandum, entered into in connection with this Agreement are true and correct
as of the date hereof.

 

		III.	REPRESENTATIONS BY AND COVENANTS OF THE COMPANY

 

The Company hereby represents
and warrants to the Subscriber that:

 

3.1   
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and
in good standing under the laws of the State of Nevada and has full corporate power and authority to own and use its properties
and its assets and conduct its business as currently conducted. Each of the Company’s subsidiaries identified on Schedule
3.1 hereto (the “Subsidiaries”) is an entity duly organized, validly existing and in good standing under the laws
of the jurisdiction of its incorporation with the requisite corporate power and authority to own and use its properties and assets
and to conduct its business as currently conducted. Neither the Company, nor any of its Subsidiaries is in violation of any of
the provisions of their respective articles of incorporation, by-laws or other organizational or charter documents, including,
but not limited to the Charter Documents (as defined below). Each of the Company and its Subsidiaries is duly qualified to conduct
business and is in good standing as a foreign corporation in each jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the
case may be, would not result in a direct and/or indirect (i) material adverse effect on the legality, validity or enforceability
of any of the Securities and/or this Agreement, (ii) material adverse effect on the results of operations, assets, business,
condition (financial and other) or prospects of the Company and its Subsidiaries, taken as a whole, or (iii) material adverse effect
on the Company’s ability to perform in any material respect on a timely basis its obligations under the Transaction Documents
(any of (i), (ii) or (iii), a “Material Adverse Effect”).

 

    	2

    	 

    

 

3.2   
Capitalization and Voting Rights. The authorized, issued and outstanding capital stock of the Company is as set forth
in Schedule 3.2 hereto and all issued and outstanding shares of capital stock of the Company are validly issued, fully paid
and nonassessable. Except as set forth in Schedule 3.2 hereto, (i) there are no outstanding securities of the Company or
any of its Subsidiaries which contain any preemptive, redemption or similar provisions, nor is any holder of securities of the
Company or any Subsidiary entitled to preemptive or similar rights arising out of any agreement or understanding with the Company
or any Subsidiary by virtue of any of the Transaction Documents, and there are no contracts, commitments, understandings or arrangements
by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries;
(ii) neither the Company nor any Subsidiary has any stock appreciation rights or "phantom stock" plans or agreements
or any similar plan or agreement; and (iii) except as set forth in Schedule 3.2 there are no outstanding options, warrants, agreements,
convertible securities, preemptive rights or other rights to subscribe for or to purchase or acquire, any shares of capital stock
of the Company or any Subsidiary or contracts, commitments, understandings, or arrangements by which the Company or any Subsidiary
is or may become bound to issue any shares of capital stock of the Company or any Subsidiary, or securities or rights convertible
or exchangeable into shares of capital stock of the Company or any Subsidiary. Except as set forth in Schedule 3.2 and as
otherwise required by law, there are no restrictions upon the voting or transfer of any of the shares of capital stock of the Company
pursuant to the Company’s Charter Documents (as defined below) or other governing documents or any agreement or other instruments
to which the Company is a party or by which the Company is bound. All of the issued and outstanding shares of capital stock of
the Company are validly issued, fully paid and nonassessable and the shares of capital stock of the Subsidiaries are owned by the
Company, free and clear of any mortgages, pledges, liens, claims, charges, encumbrances or other restrictions (collectively, “Encumbrances”).
All of such outstanding capital stock has been issued in compliance with applicable federal and state securities laws. The issuance
and sale of the Securities and, upon issuance, the Shares, as contemplated hereby will not obligate the Company to issue shares
of Common Stock or other securities to any other person (other than the Subscriber) and except as set forth in Schedule 3.2
will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding security. The Company
does not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement in effect giving
any person the right to purchase any equity interest in the Company upon the occurrence of certain events.

 

3.3   
Authorization; Enforceability.The Company has all corporate right, power and authority to enter into, execute and
deliver this Agreement and each other agreement, document, instrument and certificate to be executed by the Company in connection
with the consummation of the transactions contemplated hereby, including, but not limited to Transaction Documents and to perform
fully its obligations hereunder and thereunder. All corporate action on the part of the Company, its directors and stockholders
necessary for the (a) authorization execution, delivery and performance of this Agreement and the Transaction Documents by the
Company; and (b) authorization, sale, issuance and delivery of the Securities and upon issuance, the Shares contemplated hereby
and the performance of the Company’s obligations under this Agreement and the Transaction Documents has been taken. This
Agreement and the Transaction Documents have been duly executed and delivered by the Company and each constitutes a legal, valid
and binding obligation of the Company, enforceable against the Company in accordance with its respective terms, subject to laws
of general application relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance,
injunctive relief or other equitable remedies, and to limitations of public policy. The Securities are duly authorized and, when
issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable,
free and clear of all Encumbrances other than restrictions on transfer provided for in the Transaction Documents. The Shares, when
issued and paid for in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable,
free and clear of all Encumbrances imposed by the Company other than restrictions on transfer provided for in the Transaction Documents.
The Company has reserved a sufficient number of Warrant Shares for issuance upon the exercise of the Warrants, free and clear of
all Encumbrances, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities
laws. Except as set forth on Schedule 3.3 hereto, the issuance and sale of the Securities contemplated hereby will not give
rise to any preemptive rights or rights of first refusal on behalf of any person other than the Subscribers.

 

    	3

    	 

    

 

3.4   
No Conflict; Governmental Consents.

 

(a)            
The execution and delivery by the Company of this Agreement and the Transaction Documents, the issuance and sale of the
Securities (including, when issued, the Shares) and the consummation of the other transactions contemplated hereby or thereby do
not and will not (i) result in the violation of any law, statute, rule, regulation, order, writ, injunction, judgment or decree
of any court or governmental authority to or by which the Company is bound including without limitation all foreign, federal, state
and local laws applicable to its business and all such laws that affect the environment, except in each case as could not have
or reasonably be expected to result in a Material Adverse Effect, (ii) conflict with or violate any provision of the Company’s
Articles of Incorporation (the “Articles”), as amended or the Bylaws, (and collectively with the Articles, the “Charter
Documents”) of the Company, and (iii) conflict with, or result in a material breach or violation of, any of the terms or
provisions of, or constitute (with or without due notice or lapse of time or both) a default or give to others any rights of termination,
amendment, acceleration or cancellation (with or without due notice, lapse of time or both) under any agreement, credit facility,
lease, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which the Company or any
Subsidiary is a party or by which any of them is bound or to which any of their respective properties or assets is subject, nor
result in the creation or imposition of any Encumbrances upon any of the properties or assets of the Company or any Subsidiary.

 

(b)           
No approval by the holders of Common Stock, or other equity securities of the Company is required to be obtained by the
Company in connection with the authorization, execution, delivery and performance of this Agreement and the other Transaction Documents
or in connection with the authorization, issue and sale of the Securities and, upon issuance, the Shares, except as has been previously
obtained.

 

(c)            
No consent, approval, authorization or other order of any governmental authority or any other person is required to be obtained
by the Company in connection with the authorization, execution, delivery and performance of this Agreement and the other Transaction
Documents or in connection with the authorization, issue and sale of the Securities and, upon issuance, the Shares, except such
post-sale filings as may be required to be made with the SEC, FINRA and with any state or foreign blue sky or securities regulatory
authority, all of which shall be made when required.

 

3.5   
Consents of Third Parties.No vote, approval or consent of any holder of capital stock of the Company or any other
third parties is required or necessary to be obtained by the Company in connection with the authorization, execution, deliver and
performance of this Agreement and the other Transaction Documents or in connection with the authorization, issue and sale of the
Securities and, upon issuance, the Shares, except as previously obtained, each of which is in full force and effect.

 

3.6   
Shell Company Status; SEC Reports; Financial Statements. The Company has never been an issuer subject to Rule 144(i)
under the Securities Act. The Company has (a) for the twenty-four (24) months preceding the filing of the Company’s Annual
Report on Form 10-K of the fiscal year ended March 31, 2013 (the “2013 10-K”) (or such shorter period as the Company
was required by law to file such reports) (i) disclosed all material information required to be publicly disclosed by it on Form
8-K, (ii) filed all reports on Form 10-Q and Form 10-K and (iii) filed all other reports (other than any Form 8-K) required to
be filed by it under the Securities Act and the Securities Exchange Act of 1934, as amended, including pursuant to Section 13(a)
or 15(d) thereof (the “Exchange Act”) and (b) since the filing of the 2013 10-K, the Company has filed all reports
required to be filed by it under the Securities Act and Exchange Act, (the foregoing materials being collectively referred to herein
as the "SEC Reports" and, together with the Schedules to this Agreement (if any), the "Disclosure Materials")
on a timely basis or has timely filed a valid extension of such time of filing and has filed any such SEC Reports prior to the
expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements
of the Exchange Act and the rules and regulations of the SEC promulgated thereunder, and none of the SEC Reports, when filed, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules
and regulations of the SEC with respect thereto as in effect at the time of filing. Such financial statements have been prepared
in accordance with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis during
the periods involved, except as may be otherwise specified in such financial statements or the footnotes thereto, and fairly present
in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments.

    	4

    	 

    

 

3.7   
Licenses. Except as otherwise set forth in the SEC Reports, the Company and its Subsidiaries have sufficient licenses,
permits and other governmental authorizations currently required for the conduct of their respective businesses or ownership of
properties and is in all material respects in compliance therewith.

 

3.8   
Litigation. Except as set forth in the SEC Reports, the Company knows of no pending or threatened legal or governmental
proceedings against the Company or any Subsidiary which could materially adversely affect the business, property, financial condition
or operations of the Company and its Subsidiaries, taken as a whole, or which materially and adversely questions the validity of
this Agreement or the other Transaction Documents or the right of the Company to enter into this Agreement and the other Transaction
Documents, or to perform its obligations hereunder and thereunder. Neither the Company nor any Subsidiary is a party or subject
to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality which
could materially adversely affect the business, property, financial condition or operations of the Company and its Subsidiaries
taken as a whole. Except as set forth in the SEC Reports, there is no action, suit, proceeding or investigation by the Company
or any Subsidiary currently pending in any court or before any arbitrator or that the Company or any Subsidiary intends to initiate.
Neither the Company nor any Subsidiary, nor any director or officer thereof, is or since the Form 10-K has been the subject of
any action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the Company’s knowledge, there is not pending or contemplated, any investigation by the
SEC involving the Company or any current or former director or officer of the Company.

 

3.9   
Compliance. Except as set forth in the SEC Reports or on Schedule 3.9, neither the Company nor any Subsidiary:
(i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time
or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice
of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement
or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation
has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without
limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety,
product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to
result in a Material Adverse Effect.

 

3.10
Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued
by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as
currently conducted, except where the failure to possess such permits could not reasonably be expected to result in a Material
Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings
relating to the revocation or modification of any Material Permit.

 

3.11
FDA. The Company’s Hemopurifier product is subject to the jurisdiction of the Center for Devices of Radiological
Health (CDRH) a division of the U.S. Food and Drug Administration (“FDA”) and may be subject to the Federal Food, Drug
and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”). The Hemopurifier iscurrently manufactured, tested,
distributed, and/or marketed by the Company and/or its Subsidiaries or outsourced vendors in compliance with all applicable requirements
established by the CDRH and other federal or state laws, rules and regulations applicable to the clinical testing and development
of the Hemopurifier, except where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect.
There is no pending, completed or, to the Company’s knowledge, threatened, action from the FDA or any other governmental
entity (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning
letter or other communication from the FDA or any other governmental entity, which retracts any portion of the Investigational
Device Exemption (IDE) for the Hemopurifier in the United States as approved by the FDA on June 25, 2013. The Company has
not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product
currently developed, produced or marketed by the Company.

 

3.12
Investment Company. The Company is not an “investment company” within the meaning of such term under
the Investment Company Act of 1940, as amended, and the rules and regulations of the SEC thereunder.

 

3.13
Brokers. Except for the fees payable to the Placement Agent as set forth on Schedule 3.13, neither the Company
nor any of the Company's officers, directors, employees or stockholders has employed or engaged any broker or finder in connection
with the transactions contemplated by this Agreement and no fee or other compensation is or will be due and owing to any broker,
finder, underwriter, placement agent or similar person in connection with the transactions contemplated by this Agreement. The
Company is not party to any agreement, arrangement or understanding whereby any person has an exclusive right to raise funds and/or
place or purchase any debt or equity securities for or on behalf of the Company.

 

    	5

    	 

    

 

3.14
Intellectual Property; Employees.

 

(a)            
The Company owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights,
trade secrets, licenses, information and other proprietary rights and processes necessary for its business as now conducted and
as presently proposed to be conducted, without any known infringement of the rights of others as described in the SEC Reports and
which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”).
Except as disclosed on Schedule 3.14 or the SEC Reports, there are no material outstanding options, licenses or agreements
of any kind relating to the Intellectual Property Rights, nor is the Company bound by or a party to any material options, licenses
or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses,
information and other proprietary rights and processes of any other person or entity other than such licenses or agreements arising
from the purchase of “off the shelf” or standard products. The Company has not received any written communications
alleging that the Company has violated or, by conducting its business as presently proposed to be conducted, would violate any
Intellectual Property Rights of any other person or entity. The Company and its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect

 

(b)           
Except as disclosed in the SEC Reports, the Company is not aware that any of its employees is obligated under any contract
(including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of
any court or administrative agency, that would interfere with their duties to the Company or that would conflict with the Company’s
business as presently conducted.

 

(c)            
Neither the execution nor delivery of this Agreement, nor the carrying on of the Company’s business by the employees
of the Company, nor the conduct of the Company’s business as presently conducted, will, to the Company’s knowledge,
conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant
or instrument under which any employee is now obligated.

 

(d)           
To the Company’s knowledge, no employee of the Company, nor any consultant with whom the Company has contracted, is
in violation of any term of any employment contract, proprietary information agreement or any other agreement relating to the right
of any such individual to be employed by, or to contract with, the Company because of the nature of the business conducted by the
Company; and to the Company’s knowledge the continued employment by the Company of its present employees, and the performance
of the Company’s contracts with its independent contractors, will not result in any such violation. The Company has not received
any written notice alleging that any such violation has occurred. Except as described in SEC Reports, no employee of the Company
has been granted the right to continued employment by the Company or to any compensation following termination of employment with
the Company except for any of the same which would not have a Material Adverse Effect on the business of the Company. The Company
is not aware that any officer, key employee or group of employees intends to terminate his, her or their employment with the Company,
nor does the Company have a present intention to terminate the employment of any officer, key employee or group of employees.

    	6

    	 

    

 

3.15
Title to Properties and Assets; Liens, Etc. Except as described in the SEC Reports, the Company has good and marketable
title to its properties and assets, including the properties and assets reflected in the most recent balance sheet included in
the Company’s financial statements, and good title to its leasehold estates, in each case subject to no Encumbrances, other
than (a) those resulting from taxes which have not yet become delinquent; and (b) Encumbrances which do not materially detract
from the value of the property subject thereto or materially impair the operations of the Company; and (c) those that have otherwise
arisen in the ordinary course of business, none of which are material. Except as set forth in Schedule 3.15, the Company
is in compliance with all material terms of each lease to which it is a party or is otherwise bound.

 

3.16
Obligations to Related Parties. Except as described in the SEC Reports and in Schedule 3.16, there are no
obligations of the Company to officers, directors, stockholders, or employees of the Company other than (a) for payment of salary
or other compensation for services rendered, (b) reimbursement for reasonable expenses incurred on behalf of the Company and (c)
for other standard employee benefits made generally available to all employees (including stock option agreements outstanding under
any stock option plan approved by the Board of Directors of the Company). Except as disclosed in the SEC Reports, none of the officers
or directors of the Company and, to the Company’s knowledge, none of the employees of the Company is presently a party to
any transaction with the Company or any Subsidiary (other than as holders of stock options and/or warrants, and for services as
employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services
to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer,
director or such employee or, to the Company’s knowledge, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee or partner.

 

3.17
Material Changes. Except as set forth in Schedule 3.17, since the date of the latest audited financial statements
included within the SEC Reports, except as specifically disclosed in the subsequent SEC Reports, (i) there has been no event, occurrence
or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not
incurred any liabilities (contingent or otherwise) other than (A) trade payables, accrued expenses and other liabilities incurred
in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company's
financial statements pursuant to generally accepted accounting principles or required to be disclosed in filings made with the
SEC, (iii) the Company has not altered its method of accounting or the identity of its auditors, (iv) the Company has not declared
or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements
to purchase or redeem any shares of its capital stock, and (v) the Company has not issued any equity securities to any officer,
director or affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the SEC
any request for confidential treatment of information.

 

3.18
Sarbanes-Oxley. The Company is in compliance with all effective requirements of the Sarbanes-Oxley Act of 2002, as
amended, and the rules and regulations thereunder, that are applicable to it, except where such noncompliance could not have or
reasonably be expected to result in a Material Adverse Effect.

 

3.19
No General Solicitation. None of the Company, its Subsidiaries, any of their affiliates, and any person acting
on their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D
under the Securities Act) in connection with the offer or sale of the Securities.

 

3.20
No Integrated Offering. Assuming the accuracy of the Subscriber representations and warranties set forth in
Article I hereunder, none of the Company, its Subsidiaries, any of their affiliates, and any person acting on their behalf has,
directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would require registration of any of the Securities under the Securities Act or that is likely to cause this offering of the
Securities to be integrated with prior offerings by the Company for purposes of the Securities Act or any applicable stockholder
approval provisions, including without limitation, under the rules and regulations of any exchange or automated quotation system
on which any of the securities of the Company are listed or designated. Except as disclosed in the SEC Reports, none of the Company,
its Subsidiaries, their affiliates and any person acting on their behalf, have taken any action or steps referred to in the preceding
sentence that would require registration of any of the Securities under the Securities Act or cause the offering of the Securities
to be integrated with other offerings.

    	7

    	 

    

 

3.21
Application of Takeover Protections. The Company has taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other
similar anti-takeover provision under the Company's Charter Documents or the laws of its state of incorporation that is or could
become applicable to the Subscriber as a result of the Subscriber and the Company fulfilling their obligations or exercising their
rights under this Agreement, including, without limitation, the Company's issuance of the Securities and the Subscriber' ownership
of the Securities.

 

3.22
Taxes. Each of the Company and its Subsidiaries has filed all U.S. federal, state, local and foreign tax returns
which are required to be filed by each of them and all such returns are true and correct in all material respects, except for such
failures to file which could not reasonably be expected to have a Material Adverse Effect. The Company and each Subsidiary has
paid all taxes pursuant to such returns or pursuant to any assessments received by any of them or by which any of them are obligated
to withhold from amounts owing to any employee, creditor or third party. The Company and each Subsidiary has properly accrued all
taxes required to be accrued and/or paid, except where the failure to accrue would not have a Material Adverse Effect. To the knowledge
of the Company, the tax returns of the Company and its Subsidiaries are not currently being audited by any state, local or federal
authorities. Neither the Company nor any Subsidiary has waived any statute of limitations with respect to taxes or agreed to any
extension of time with respect to any tax assessment or deficiency. The Company has set aside on its books adequate provision for
the payment of any unpaid taxes.

 

3.23
Registration Rights. Except as set forth on Schedule 3.23, no person has any right to cause the Company to
effect the registration under the Securities Act of any securities of the Company.

 

3.24
Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act nor has the Company received any notification that the SEC is contemplating
terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any trading
market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing
or maintenance requirements of such trading market. The Company is, and has no reason to believe that it will not in the foreseeable
future continue to be, in compliance with all such listing and maintenance requirements

 

3.25
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Offering
Materials, the Company confirms that neither it nor any other person acting on its behalf has provided the Subscriber or its agents
or counsel with any information that it believes constitutes or might constitute material, non-public information. The Company
understands and confirms that the Subscriber will rely on the foregoing representation in effecting transactions in securities
of the Company. All disclosure furnished by or on behalf of the Company to the Subscriber regarding the Company, its business and
the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain
any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein,
in light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during
the twelve months preceding the date of this Agreement taken as a whole together the SEC Reports do not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements,
in light of the circumstances under which they were made and when made, not misleading.

 

3.26
Private Placement. Assuming the accuracy of the Subscribers’ representations and warranties set forth in Section
1, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Subscriber
as contemplated hereby.

 

3.27
DTC Status. The Company’s transfer agent (the “Transfer Agent”) is a partial member participant
of the Depository Trust Company Automated Securities Transfer Program. The Company's Common Stock is currently eligible for transfer
pursuant to the Depository Trust Company Automated Securities Transfer Program.

 

3.28
OFAC. Neither the Company nor, to the Company’s knowledge, any director, officer, agent, employee, affiliate
or person acting on its behalf, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control
of the U.S. Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds of the sale
of the Units, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other person or entity,
towards any sales or operations in Cuba, Iran, Syria, Sudan, Myranmar or any other country sanctioned by OFAC or for the purpose
of financing the activities of any person currently subject to any U.S. sanctions.

    	8

    	 

    

 

 

3.29
Bad Actor Disqualification

 

(a)    
No Disqualification Events. With respect to Securities to be offered and sold hereunder in reliance on Rule 506 under
the Securities Act ("Regulation D Securities"), none of the Company, any of its predecessors, any affiliated issuer,
any director, executive officer, other officer of the Company participating in the offering, any beneficial owner of 20% or more
of the Company's outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term
is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an "Issuer
Covered Person" and, together, "Issuer Covered Persons") is subject to any of the "Bad Actor" disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a "Disqualification Event"), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person
is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under
Rule 506(e), and has furnished to the Placement Agent and the Subscriber a copy of any disclosures provided thereunder.

 

(b)    
Other Covered Persons. The Company is not aware of any person that (i) has been or will be paid (directly or indirectly)
remuneration for solicitation of purchasers in connection with the sale of the Securities and (ii) who is subject to a Disqualification
Event.  

 

(c)    
Notice of Disqualification Events. The Company will notify the Placement Agent in writing of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification
Event relating to any Issuer Covered Person, prior to any Closing of this Offering.

 

		IV.	TERMS OF SUBSCRIPTION

 

4.1   
The Securities will be offered for sale until the earlier of (i) the date upon which subscriptions for the Maximum Offering
offered hereunder have been accepted, (ii) November 30, 2013 (subject to the right of the Company and the Placement Agent to extend
the offering until December 31, 2013 without further notice to investors), or (iii) the date upon which the Company and the Placement
Agent elect to terminate the Offering (the “Termination Date”). The Offering is being conducted on a “reasonable
efforts, all or none” basis with respect to the Minimum Offering and thereafter on a “reasonable efforts”
basis for up to the Maximum Offering.

 

4.2   
The Company may hold an initial closing (“Initial Closing”) at any time after the receipt of accepted subscriptions
for the Minimum Offering. After the Initial Closing, subsequent closings with respect to additional Securities may take place at
any time prior to the Termination Date as determined by the Company, with respect to subscriptions accepted prior to the Termination
Date (each such closing, together with the Initial Closing, being referred to as a “Closing”). The last Closing of
the Offering, occurring on or prior to the Termination Date, shall be referred to as the “Final Closing”. Any subscription
documents or funds received after the Final Closing will be returned, without interest or deduction. In the event that the any
Closing does not occur prior to the Termination Date, all amounts paid by the Subscriber shall be returned to the Subscriber, without
interest or deduction. The Subscriber may revoke its subscription and obtain a return of the subscription amount paid to the Escrow
Account at any time before the date of the Initial Closing by providing written notice to the Placement Agent, the Company and
the Escrow Agent as provided in Section 6.1 below. Upon receipt of a revocation notice from the Subscriber prior to the date of
the Initial Closing, all amounts paid by the Subscriber shall be returned to the Subscriber, without interest or deduction. The
Subscriber may not revoke this subscription or obtain a return of the subscription amount paid to the Escrow Agent on or after
the date of the Initial Closing. Any subscription received after the Initial Closing but prior to the Termination Date shall be
irrevocable.

 

4.3   
The minimum purchase that may be made by any prospective investor shall be $12,500. Subscriptions
for investment below the minimum investment may be accepted at the discretion of the Placement Agent and the Company. The Company
and the Placement Agent reserve the right to reject any subscription made hereby, in whole or in part, in their sole discretion.
The Company’s agreement with each Subscriber is a separate agreement and the sale of the Securities to each Subscriber is
a separate sale.

 

4.4   
All funds shall be deposited in the account identified in Section 1.1 hereof.

 

4.5   
Certificates representing the Securities purchased by the Subscriber pursuant to this Agreement will be prepared for delivery
to the Subscriber as soon as practicable following the Closing (but in no event later than five (5) days after a Closing) at which
such purchase takes place. The Subscriber hereby authorizes and directs the Company to deliver the certificates representing the
Securities purchased by the Subscriber pursuant to this Agreement directly to the Subscriber’s residential or business or
brokerage house address indicated on the signature page hereto.

 

4.6   
The Company’s agreement with each Subscriber is a separate agreement and the sale of Securities to each Subscriber
is a separate sale.

 

    	9

    	 

    

 

		V.	CONDITIONS TO OBLIGATIONS OF THE SUBSCRIBER

 

5.1   
The Subscriber’s obligation to purchase the Securities at the Closing at which such purchase is to be consummated
is subject to the fulfillment on or prior to such Closing of the following conditions, which conditions may be waived at the option
of each Subscriber to the extent permitted by law:

 

(a)            
Representations and Warranties; Covenants. The representations and warranties made by the Company in Section 3 hereof
qualified as to materiality shall be true and correct as of the Initial Closing and on each Closing Date, except (i) to the extent
any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall
be true and correct as of such earlier date, and, (ii) the representations and warranties made by the Company in Section 3 hereof
not qualified as to materiality shall be true and correct in all material respects at all times prior to and on the Closing Date,
except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation
or warranty shall be true and correct in all material respects as of such earlier date; provided however, that notwithstanding
the foregoing, the Company shall only be required to update the Disclosure Schedules by the delivery to the Subscribers by the
Company of an amended Disclosure Schedule with respect to any information that is of a material nature as of such proposed Closing
Date. All covenants, agreements and conditions contained in this Agreement to be performed by the Company on or prior to the date
of such Closing shall have been performed or complied with in all material respects.

 

(b)           
No Legal Order Pending. There shall not then be in effect any legal or other order enjoining or restraining the transactions
contemplated by this Agreement.

 

(c)            
No Law Prohibiting or Restricting Such Sale. There shall not be in effect any law, rule or regulation prohibiting
or restricting such sale or requiring any consent or approval of any person, which shall not have been obtained, to issue the Securities
(except as otherwise provided in this Agreement).

 

(d)           
Required Consents. The Company shall have obtained any and all consents, permits, approvals, registrations and waivers
necessary or appropriate for consummation of the purchase and sale of the Securities and the consummation of the other transactions
contemplated by the Transaction Documents, all of which shall be in full force and effect.

 

(e)Adverse
Changes. Since the date of execution of this Agreement, no event or series of events shall have occurred that reasonably could
have or result in a Material Adverse Effect.

 

(f)No
Suspensions of Trading in Common Stock; Listing. Trading in the Common Stock shall not have been suspended by the SEC or any
trading market (except for any suspensions of trading of not more than one trading day solely to permit dissemination of material
information regarding the Company) at any time since the date of execution of this Agreement, and the Common Stock shall have been
at all times since such date listed for trading on a trading market.

 

(g)Blue
Sky. The Company shall have completed qualification for the Securities and the Shares under applicable Blue Sky laws.

 

(h)Legal
Opinion. The Company’s corporate counsel shall have delivered a legal opinion addressed to the Subscribers in a form
reasonably acceptable to the Placement Agent.

 

(i)Proceedings
and Litigation. No action, suit or proceeding shall have been commenced by any Person against any party hereto seeking to restrain
or delay the purchase and sale of the Units or the other transactions contemplated by this Agreement or any of the other Offering
Documents.

    	10

    	 

    

 

 

(j)Disclosure
Schedules. The Company shall have delivered a copy of its Disclosure Schedules (or amended Disclosure Schedules) qualifying
any of the representations and warranties contained in Section 3 which original Disclosure Schedules will speak only as Initial
Closing.

 

		VI.	COVENANTS OF THE COMPANY

 

6.1   
Transfer Restrictions.

 

(a)            
The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer
of Securities other than pursuant to an effective registration statement or Rule 144 promulgated under the Securities Act, to the
Company or to an affiliate of a Subscriber or in connection with, the Company may require the transferor thereof to provide to
the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of
which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of
such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to
be bound by the terms of this Agreement, and shall have the rights of a Subscriber under this Agreement.

 

(b)           
The Subscriber agrees to the imprinting, so long as is required by this Section 5.1, of a legend on any of the Securities,
including the Shares, in the following form:

 

[NEITHER]
THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE] [CONVERTIBLE]] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES
AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY
A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY [AND THE SECURITIES ISSUABLE UPON [EXERCISE] [CONVERSION] OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA
FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

(c)            
Certificates evidencing the Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof):
(i) while a registration statement covering the resale of such security is effective under the Securities Act, or (ii) following
any sale of such Shares pursuant to Rule 144, or (iii) if such Shares are eligible for sale under Rule 144, without the requirement
for the Company to be in compliance with the current public information required under Rule 144 as to such Shares and without volume
or manner-of-sale restrictions or (iv) if such legend is not required under applicable requirements of the Securities Act (including
judicial interpretations and pronouncements issued by the staff of the SEC). The Company shall cause its counsel, at the Company’s
expense, to issue a legal opinion to the Company’s transfer agent promptly (but in no event later than the requisite share
delivery date set forth in the Warrants) if required by the Company’s transfer to effect the removal of the legend hereunder.

 

    	11

    	 

    

 

6.2           
Listing of Securities. The Company agrees, (i) if the Company applies to have the Common Stock traded on any other
trading market, it will include in such application the shares of Common Stock and Shares, and will take such other action as is
necessary or desirable to cause the shares of Common Stock and Shares to be listed on such other trading market as promptly as
possible, and (ii) it will take all action reasonably necessary to continue the listing and trading of its Common Stock on a trading
market and will comply in all material respects with the Company’s reporting, filing and other obligations under the bylaws
or rules of the trading market.

 

6.3   
Reservation of Shares. The Company shall at all times while the Warrants are outstanding maintain a reserve from
its duly authorized shares of Common Stock of a number of shares of Common Stock sufficient to allow for the issuance of the Warrant
Shares.

 

6.4   
Replacement of Securities. If any certificate or instrument evidencing any Securities or the Shares is mutilated,
lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation
thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably
satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested. The applicants
for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the
issuance of such replacement securities. If a replacement certificate or instrument evidencing any securities is requested due
to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent
to any issuance of a replacement.

 

6.5   
Furnishing of Information. Until the time that no Subscriber owns Securities, the Company covenants to maintain the
registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant
to the Exchange Act. As long as Subscriber owns Securities, if the Company is not required to file reports pursuant to the Exchange
Act, it will prepare and furnish to Subscriber and make publicly available in accordance with Rule 144(c) such information as is
required for the Subscribers to sell the Securities under Rule 144. The Company further covenants that it will take such further
action as any holder of Securities may reasonably request, to the extent required from time to time to enable such person to sell
such Securities without registration under the Securities Act within the requirements of the exemption provided by Rule 144.

 

6.6   
Securities Laws; Publicity. The Company shall, by 8:30 a.m. (New York City time) on the second trading day immediately
following a Closing hereunder, issue a Current Report on Form 8-K disclosing the material terms of the transactions contemplated
hereby and including the Transaction Documents as exhibits thereto to the extent required by law. The Company shall not publicly
disclose the name of Subscriber, or include the name of any Subscriber in any filing with the SEC or any regulatory agency or trading
market, without the prior written consent of Subscriber, except: (a) as required by federal securities law in connection with the
filing of final Transaction Documents (including signature pages thereto) with the SEC and (b) to the extent such disclosure is
required by law, in which case the Company shall provide the Subscriber with prior notice of such disclosure permitted under this
clause (b).

 

6.7   
Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under
Regulation D promulgated under the Securities Act and to provide a copy thereof, promptly upon request of the Subscriber. The Company
shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify
the Securities for, sale to the Subscriber at the Closing under applicable securities or “Blue Sky” laws of the states
of the United States, and shall provide evidence of such actions promptly upon request of any Subscriber.

 

6.8   
Equal Treatment of Subscribers. No consideration (including any modification of any Transaction Document) shall be
offered or paid to any person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents
unless the same consideration is also offered to all of the parties to the Transaction Documents.

    	12

    	 

    

 

6.9   
Indemnification. 

 

(a)     
The Company agrees to indemnify and hold harmless the Subscriber, its affiliates and their respective officers, directors,
employees, agents and controlling persons (collectively, the “Indemnified Parties”) from and against , any and all
loss, liability, damage or deficiency suffered or incurred by any Indemnified Party by reason of any misrepresentation or breach
of warranty by the Company or,after any applicable notice and/or cure periods, nonfulfillment
of any covenant or agreement to be performed or complied with by the Company under this Agreement, the Transaction Documents; and
will promptly reimburse the Indemnified Parties for all expenses (including reasonable fees and expenses of legal counsel) as incurred
in connection with the investigation of, preparation for or defense of any pending or threatened claim related to or arising in
any manner out of any of the foregoing, or any action or proceeding arising therefrom (collectively, “Proceedings”),
whether or not such Indemnified Party is a formal party to any such Proceeding.

 

(b)     
If for any reason (other than a final non-appealable judgment finding any Indemnified Party liable for losses, claims, damages,
liabilities or expenses for its gross negligence or willful misconduct) the foregoing indemnity is unavailable to an Indemnified
Party or insufficient to hold an Indemnified Party harmless, then the Company shall contribute to the amount paid or payable by
an Indemnified Party as a result of such loss, claim, damage, liability or expense in such proportion as is appropriate to reflect
not only the relative benefits received by the Company on the one hand and the Advisor on the other, but also the relative fault
by the Company and the Indemnified Party, as well as any relevant equitable considerations.

 

6.10Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company covenants and agrees that neither it, nor any other person acting on its behalf, will provide Subscriber or its agents
or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto Subscriber
shall have executed a written agreement regarding the confidentiality and use of such information. The Company understands and
confirms that Subscriber shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

 

6.11Use
of Proceeds. Except as set forth on Schedule 6.11 attached hereto, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and shall not use such proceeds for: (a) the satisfaction of any portion
of the Company’s debt (other than payment of trade payables in the ordinary course of the Company’s business and prior
practices), (b) the redemption of any Common Stock or Common Stock equivalents or (c) the settlement of any outstanding litigation.

 

    	13

    	 

    

 

 

		VII.	MISCELLANEOUS

 

7.1   
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing
and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile or by electronic communication at or prior to 5:30 p.m. (New York City time) on a day in which the New York Stock
Exchange is open for trading (a “Trading Day”), (b) the next Trading Day after the date of transmission, if such notice
or communication is delivered via facsimile or electronic communication on a day that is not a Trading Day or later than 5:30 p.m.
(New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by
U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to
be given. The address for such notices and communications shall be addressed as follows:

 

if to the
Company, to it at:

 

Aethlon Medical, Inc.

8910 University Center Lane, Suite 660

San Diego, California 92122

Attn: James A. Joyce, CEO

 

With a copy to (which shall not constitute notice):

 

Post Law Group, PC

5900 Wilshire Boulevard, Suite 620

Los Angeles, CA 90036Attn: Jennifer A. Post, Esq.

if to the Subscriber, to the Subscriber’s
address indicated on the signature page of this Agreement.

 

With a copy to (which shall not constitute notice):

 

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, NY 10006

Attn: Richard A. Friedman, Esq.

 

if to the Escrow Agent, to it at:

 

_________________

_________________

_________________

_________________

_________________

 

7.2   
Except as otherwise provided herein, this Agreement shall not be changed, modified or amended except by a writing signed
by the Company and the parties to be charged, and this Agreement may not be discharged except by performance in accordance with
its terms or by a writing signed by the party to be charged. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default
or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any
right hereunder in any manner impair the exercise of any such right.

 

7.3   
This Agreement shall be binding upon and inure to the benefit of the parties hereto and to their respective heirs, legal
representatives, successors and assigns. The Company may not assign this Agreement or any rights or obligations hereunder without
the prior written consent of Subscriber (other than by merger). Subscriber may assign any or all of its rights under this Agreement
to any person to whom Subscriber assigns or transfers any Securities, provided that such transferee agrees in writing to be bound,
with respect to the transferred Securities, by the provisions of the Transaction Documents.

 

    	14

    	 

    

 

7.4   
The Transaction Documents and the Offering Materials, together with the exhibits and schedules thereto, contain the entire
understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral
or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

7.5   
Upon the execution and delivery of this Agreement by the Subscriber and the Company, this Agreement shall become a binding
obligation of the Subscriber with respect to the purchase of Securities as herein provided, subject, however, to the right hereby
reserved by the Company to enter into the same agreements with other Subscriber and to reject any subscription, in whole or in
part, provided the Company returns to Subscriber any funds paid by Subscriber with respect to such rejected subscription or portion
thereof, without interest or deduction.

 

7.6   
All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state
and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the
state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper
or is an inconvenient venue for such proceeding.

 

7.7   
In order to discourage frivolous claims the parties agree that unless a claimant in any proceeding arising out of this Agreement
succeeds in establishing his claim and recovering a judgment against another party (regardless of whether such claimant succeeds
against one of the other parties to the action), then the other party shall be entitled to recover from such claimant all of its/their
reasonable legal costs and expenses relating to such proceeding and/or incurred in preparation therefor.

 

7.8   
The holding of any provision of this Agreement to be invalid or unenforceable by a court of competent jurisdiction shall
not affect any other provision of this Agreement, which shall remain in full force and effect. If any provision of this Agreement
shall be declared by a court of competent jurisdiction to be invalid, illegal or incapable of being enforced in whole or in part,
such provision shall be interpreted so as to remain enforceable to the maximum extent permissible consistent with applicable law
and the remaining conditions and provisions or portions thereof shall nevertheless remain in full force and effect and enforceable
to the extent they are valid, legal and enforceable, and no provisions shall be deemed dependent upon any other covenant or provision
unless so expressed herein.

 

7.9   
It is agreed that a waiver by either party of a breach of any provision of this Agreement shall not operate, or be construed,
as a waiver of any subsequent breach by that same party.

 

7.10
The Company agrees to execute and deliver all such further documents, agreements and instruments and take such other and
further action as may be necessary or appropriate to carry out the purposes and intent of this Agreement.

 

    	15

    	 

    

 

 

7.11
This Agreement may be executed in two or more counterparts each of which shall be deemed an original, but all of which shall
together constitute one and the same instrument. In the event that any signature is delivered by facsimile transmission or by e-mail
delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

 

7.12
Nothing in this Agreement shall create or be deemed to create any rights in any person or entity not a party to this Agreement.

 

7.13
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the
Subscriber and the Company will be entitled to specific performance under this Agreement. The parties agree that monetary damages
may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence
and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would
be adequate.

 

7.14
The Company further understands and acknowledges that (i) Subscriber may engage in hedging activities at various times during
the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Shares
deliverable with respect to Securities are being determined, and (ii) such hedging activities (if any) could reduce the value of
the existing stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted. 
The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

 

    	16

    	 

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this Unit Purchase Agreement as of the date set forth in the first paragraph hereof.

 

	
        COMPANY:

        

        AETHLON MEDICAL, INC.
	 
	
        By:_____________________________

        Name:

        Title:

        

        Address:

        

        Tel:

        Fax:

        email:
	 
	 	 
	 	 
	SUBSCRIBERS:
	  The Subscribers set forth on Exhibit A to the Agreement have executed a Subscription Agreement with the Company which provides, among other things, that by executing the Subscription Agreement each Subscriber is deemed to have executed this UNIT PURCHASE AGREEMENT in all respects and is bound to purchase the Units set forth in such Subscription Agreement and Exhibit A to the Agreement.          

 

 

    	17

    	 

    

 

 

EXHIBIT A

SCHEDULE OF SUBSCRIBERS

 

	Name of Subscriber	Units	Shares of Common Stock	Warrant Shares	Total Purchase

Price 
	 	 	 	 	 
		 	 	 	 

 

 

 

    	18Exhibit 10.2

 

To subscribe for Units

in the private offering of

AETHLON MEDICAL, INC.

 

	1.	Date and Fill in the number of units (the “Units”) (each Unit consisting of
(a) one hundred thousand (100,000) shares of the Company’s common stock par value $0.001 per share (the “Common Stock”)
at a purchase price of $0.125 per share, and (b) a five-year warrant (collectively, the “Warrants” and together with
the Units and Common Stock, the “Securities”) to purchase fifty thousand (50,000) shares of Common Stock of the Company
at an exercise price equal to $0.22 per share, subject to equitable adjustment thereunder (the “Exercise Price”) at
a negotiated price of $12,500 per Unit being subscribed for and Complete and Sign the Signature Page included in the Subscription
Agreement.

 

	2.	Initial the Accredited Investor Certification attached to this Subscription Agreement.

 

	3.	Complete and Sign the Signature Page attached to this Subscription Agreement. NOTICE:
Please note that by executing the attached Subscription Agreement, you will deemed to have executed the Unit Purchase Agreement
(Exhibit B to the Memorandum, as defined below), and agreed to the terms of the Warrant (Exhibit C to the Unit Purchase Agreement)
and all exhibits, supplements and schedules thereto, as such may be amended from time to time (collectively the “Transaction
Documents”), each of which are attached to the Memorandum, and will be treated for all purposes as if you did review, approve
and execute, if required, each such Transaction Document even though you may not have physically signed the signature pages to
such documents.

 

	4.	Complete and Return the attached Purchaser Questionnaire and, if applicable, Wire Transfer
Authorization attached to this Subscription Agreement.

 

	5.	Return all forms to your Account Executive and then send
                                 all signed original documents with a check (if applicable) to:

 

_________________

_________________

_________________

_________________

 

	6.	Please make your subscription payment payable to the order of “_________________, as Escrow
Agent for Aethlon Medical, Inc.” Account No. _________________

 

 

    	1

    	 

    

 

For wiring funds directly
to the escrow account, use the following instructions:

 

_________________

_________________

_________________

Acct. Name:

 

 

ABA Number:

SWIFT Code:

A/C Number:

 

FBO: Purchaser
Name

           Social
Security Number

           Address

 

 

 

 

 

 

 

 

 

ALL SUBSCRIPTION DOCUMENTS MUST BE FILLED
IN AND SIGNED EXACTLY AS SET FORTH WITHIN.

 

 

 

 

 

    	2

    	 

    

 

SUBSCRIPTION AGREEMENT

 

 

AETHLON MEDICAL, INC.

 

 

Aethlon Medical, Inc.

8910 University Center Lane, Suite 660

San Diego, California 92122

Attn: James A. Joyce, CEO

 

Ladies and Gentlemen:

 

1.          Subscription. The undersigned (the “Purchaser”) will purchase the number of units (collectively, the “Units”)
of securities of Aethlon Medical, Inc., a Nevada corporation (the “Company”), set forth
on the signature page to this Subscription Agreement, at a purchase price of $12,500 per Unit, with each Unit consisting
of (a) one hundred thousand (100,000) shares of the Company’s common stock par value $0.001 per share (the “Common
Stock”) at a purchase price of $0.125 per share, and (b) a five-year warrant (collectively, the “Warrants” and
together with the Units and Common Stock, the “Securities”) to purchase fifty thousand (50,000) shares of Common Stock
of the Company at an exercise price equal to $0.22 per share, subject to adjustment thereunder (the “Exercise Price”).
The Units are being offered (the “Offering”) by the Company
pursuant to the offering terms set forth in the Company’s Confidential Private Placement Memorandum, dated October 10, 2013,
as may be amended and/or supplemented, from time to time (collectively, the “Memorandum”).

 

The
Units are being offered on a “reasonable efforts, all or none” basis with respect to the minimum of $200,000 purchase
price for the Units (the “Minimum Offering”) and thereafter on a “reasonable efforts”
basis up to the maximum of $2,000,000 purchase price for the Units (the “Maximum Offering”).
The Units will be offered for sale until the earlier of (i) the date upon which subscriptions for the Maximum Offering
offered hereunder have been accepted, (ii) November 30, 2013 (subject to the right of the Company and the Placement Agent to extend
the offering until December 31, 2013 without further notice to investors), or (iii) the date upon which the Company and the Placement
Agent elect to terminate the Offering (the “Termination Date”).

 

The Company may hold an initial closing (“Initial
Closing”) at any time after the receipt of accepted subscriptions for the Minimum Offering. After the Initial Closing, subsequent
closings with respect to additional Securities may take place at any time prior to the Termination Date as determined by the Company,
with respect to subscriptions accepted prior to the Termination Date (each such closing, together with the Initial Closing, being
referred to as a “Closing”). The last Closing of the Offering, occurring on or prior to the Termination Date, shall
be referred to as the “Final Closing”. Any subscription documents or funds received after the Final Closing will be
returned, without interest or deduction. In the event that the any Closing does not occur prior to the Termination Date, all amounts
paid by the Purchaser shall be returned to the Purchaser, without interest or deduction.

 

    	3

    	 

    

 

Subscriptions for investment
below the minimum investment may be accepted at the discretion of the Placement Agent and the Company. The
Company reserves the right (but is not obligated) to have its employees, agents, officers, directors and affiliates purchase Units
in the Offering and all such purchases will be counted towards the Minimum Offering and the Maximum Offering. 

 

The terms of the Offering
are more completely described in the Memorandum and such terms are incorporated herein in their entirety. Certain capitalized terms
used, but not otherwise defined herein, will have the respective meanings provided in the Memorandum.

 

2.          Payment.
The Purchaser encloses herewith a check payable to, or will immediately make a wire transfer payment to, “_________________,
as Escrow Agent for Aethlon Medical, Inc.,” in the full amount of the purchase price of the Units being subscribed for.
Together with the check for, or wire transfer of, the full purchase price, the Purchaser is delivering a completed and executed
Signature Page to this Subscription Agreement along with a completed and executed Accredited Investor Certification, which are
annexed hereto. By executing this Subscription Agreement, you will be deemed to have executed the Unit Purchase
Agreement (Exhibit B to the Memorandum), and agreed to the terms of the Warrant (Exhibit C to the Memorandum) and all exhibits,
supplements and schedules thereto, as such may be amended from time to time (collectively the “Transaction Documents”),
each of which are attached to the Memorandum, and will be treated for all purposes as if you did review, approve and execute,
if required, each such Transaction Document even though you may not have physically signed the signature pages to such documents.

 

3.          Deposit
of Funds. All payments made as provided in Section 2 hereof will be deposited by the Purchaser as soon as practicable with
_________________, as escrow agent (the “Escrow Agent”), or such other escrow agent
appointed by ___________ and the Company, in a non-interest bearing escrow account (the “Escrow
Account”). In the event that the Company does not effect a Closing during the Offering Period, the Escrow Agent will refund
all subscription funds, without deduction and/or interest accrued thereon, and will return the subscription documents to each
Purchaser. If the Company or ___________ rejects a subscription, either in whole or in part
(at the sole discretion of the Company or ___________), the rejected subscription funds or the
rejected portion thereof will be returned promptly to such Purchaser without interest, penalty, expense or deduction.

 

4.          Acceptance
of Subscription. The Purchaser understands and agrees that the Company or ___________, each
in its sole discretion, reserves the right to accept this or any other subscription for the Units, in whole or in part, notwithstanding
prior receipt by the Purchaser of notice of acceptance of this or any other subscription. The Company will have no obligation hereunder
until the Company executes and delivers to the Purchaser an executed copy of the Purchase Agreement. If Purchaser’s subscription
is rejected in whole (at the sole discretion of the Company or ___________), the Offering is
terminated or the Minimum Offering is not subscribed for and accepted prior to the Termination Date, all funds received from the
Purchaser will be returned without interest, penalty, expense or deduction, and this Subscription Agreement will thereafter be
of no further force or effect. If Purchaser’s subscription is rejected in part (at the sole discretion of the Company or
___________) and the Company accepts the portion not so rejected, the funds for the rejected
portion of such subscription will be returned without interest, penalty, expense or deduction, and this Subscription Agreement
will continue in full force and effect to the extent such subscription was accepted. The Purchaser may revoke its subscription
and obtain a return of the subscription amount paid to the Escrow Account at any time before the date of the Initial Closing. The
Purchaser may not revoke this subscription or obtain a return of the subscription amount paid to the Escrow Agent on or after the
date of the Initial Closing. Any subscription received after the Initial Closing but prior to the Termination Date shall be irrevocable.

 

    	4

    	 

    

 

5.          Representations
and Warranties of the Purchaser. The Purchaser hereby acknowledges, represents, warrants, and agrees as follows:

 

(a)          None of the Units, the Common
Stock, the Warrants or the shares of Common Stock of the Company issuable upon exercise of the Warrants (collectively referred
to hereafter as the “Securities”) are registered under the Securities Act of 1933, as amended (the “Securities
Act”), or any state securities laws. The Purchaser understands that the offering and sale of the Securities is intended to
be exempt from registration under the Securities Act, by virtue of Section 4(2) thereof and the provisions of Regulation D promulgated
thereunder, based, in part, upon the representations, warranties and agreements of the Purchaser contained in this Subscription
Agreement and the Purchase Agreement;

 

(b)          The Purchaser and the Purchaser’s
attorney, accountant, purchaser representative and/or tax advisor, if any (collectively, “Advisors”), have received
and have carefully reviewed the Memorandum, this Subscription Agreement, and each of the Transaction Documents and all other documents
requested by the Purchaser or its Advisors, if any, and understand the information contained therein, prior to the execution of
this Subscription Agreement;

 

(c)          Neither the Securities and Exchange
Commission (the “Commission”) nor any state securities commission has approved or disapproved of the Securities or
passed upon or endorsed the merits of the Offering or confirmed the accuracy or determined the adequacy of the Memorandum. The
Memorandum has not been reviewed by any Federal, state or other regulatory authority. Any representation to the contrary may be
a criminal offense;

 

(d)          All documents, records, and
books pertaining to the investment in the Securities including, but not limited to, all information regarding the Company and the
Securities, have been made available for inspection and reviewed by the Purchaser and its Advisors, if any;

 

(e)          The Purchaser and its Advisors,
if any, have had a reasonable opportunity to ask questions of and receive answers from the Company’s officers and any other
persons authorized by the Company to answer such questions, concerning, among other related matters, the Offering, the Securities,
the Transaction Documents and the business, financial condition, results of operations and prospects of the Company and all such
questions have been answered by the Company to the full satisfaction of the Purchaser and its Advisors, if any;

 

    	5

    	 

    

 

(f)          In evaluating the suitability
of an investment in the Company, the Purchaser has not relied upon any representation or other information (oral or written) other
than as stated in the Memorandum;

 

(g)          The Purchaser is unaware of,
is in no way relying on, and did not become aware of the offering of the Securities through or as a result of, any form of general
solicitation or general advertising including, without limitation, any article, notice, advertisement or other communication published
in any newspaper, magazine or similar media or broadcast over television, radio or over the Internet, in connection with the offering
and sale of the Securities and is not subscribing for the Securities and did not become aware of the Offering through or as a result
of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by, a person not previously
known to the Purchaser in connection with investments in securities generally;

 

(h)          The
Purchaser has taken no action which would give rise to any claim by any person for brokerage commissions, finders’ fees
or the like relating to this Subscription Agreement or the transactions contemplated hereby (other than fees to be paid by the
Company to ___________, as described in the Memorandum);

 

(i)          The Purchaser, either alone
or together with its Advisors, if any, has such knowledge and experience in financial, tax, and business matters, and, in particular,
investments in securities, so as to enable it to utilize the information made available to it in connection with the Offering to
evaluate the merits and risks of an investment in the Securities and the Company and to make an informed investment decision with
respect thereto;

 

(j)          The
Purchaser is not relying on the Company, ___________ or any of their respective employees or
agents with respect to the legal, tax, economic and related considerations of an investment in any of the Securities and the Purchaser
has relied on the advice of, or has consulted with, only its own Advisors;

 

(k)          The Purchaser is acquiring the
Securities solely for such Purchaser’s own account for investment and not with a view to resale or distribution thereof,
in whole or in part. The Purchaser has no agreement or arrangement, formal or informal, with any person to sell or transfer all
or any part of any of the Securities and the Purchaser has no plans to enter into any such agreement or arrangement;

 

(l)          The Purchaser understands and
agrees that purchase of the Securities is a high risk investment and the Purchaser is able to afford an investment in a speculative
venture having the risks and objectives of the Company. The Purchaser must bear the substantial economic risks of the investment
in the Securities indefinitely because none of the Securities may be sold, hypothecated or otherwise disposed of unless subsequently
registered under the Securities Act and applicable state securities laws or an exemption from such registration is available. Legends
will be placed on the certificates representing the Common Stock, the Warrants and the shares of Common Stock issuable upon exercise
of the Warrants to the effect that such securities have not been registered under the Securities Act or applicable state securities
laws and appropriate notations thereof will be made in the Company’s books;

 

    	6

    	 

    

 

(m)          The Purchaser has adequate means
of providing for such Purchaser’s current financial needs and foreseeable contingencies and has no need for liquidity from
its investment in the Securities for an indefinite period of time;

 

(n)          The Purchaser is aware that
an investment in the Securities involves a number of very significant risks and has carefully read and considered the Company's
periodic filings with the United States Securities and Exchange Commission, and the matters set forth in the Memorandum and, in
particular, the matters under the caption “Risk Factors” therein and understands any of such risk may materially adversely
affect the Company’s operations and future prospects;

 

(o)          At
the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises
any Warrants, it will be an “accredited investor” within the meaning of Regulation D, Rule
501(a), promulgated by the Securities and Exchange Commission under the Securities Act and has truthfully and accurately completed
the Purchaser Questionnaire attached to this Subscription Agreement and will submit to the Company such further assurances of
such status as may be reasonably requested by the Company; 

 

(p)          The Purchaser: (i) if a natural
person, represents that the Purchaser has reached the age of 21 and has full power and authority to execute and deliver this Subscription
Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof; (ii) if a corporation,
partnership, or limited liability company, or association, joint stock company, trust, unincorporated organization or other entity,
represents that such entity was not formed for the specific purpose of acquiring the Securities, such entity is duly organized,
validly existing and in good standing under the laws of the state of its organization, the consummation of the transactions contemplated
hereby is authorized by, and will not result in a violation of state law or its charter or other organizational documents, such
entity has full power and authority to execute and deliver this Subscription Agreement and all other related agreements or certificates
and to carry out the provisions hereof and thereof and to purchase and hold the Securities, the execution and delivery of this
Subscription Agreement has been duly authorized by all necessary action, this Subscription Agreement has been duly executed and
delivered on behalf of such entity and is a legal, valid and binding obligation of such entity; or (iii) if executing this Subscription
Agreement in a representative or fiduciary capacity, represents that it has full power and authority to execute and deliver this
Subscription Agreement in such capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation,
or limited liability company or partnership, or other entity for whom the Purchaser is executing this Subscription Agreement, and
such individual, partnership, ward, trust, estate, corporation, or limited liability company or partnership, or other entity has
full right and power to perform pursuant to this Subscription Agreement and make an investment in the Company, and represents that
this Subscription Agreement constitutes a legal, valid and binding obligation of such entity. The execution and delivery of this
Subscription Agreement will not violate or be in conflict with any order, judgment, injunction, agreement or controlling document
to which the Purchaser is a party or by which it is bound;

 

    	7

    	 

    

 

(q)          The
Purchaer hereby acknowledges receipt and careful review of this Agreement, the Memorandum, the Warrant and all other exhibits,
annexes and appendices thereto (collectively referred to as the “Offering Materials”), and has had access to the Company’s
Annual Report on Form 10-K and the exhibits thereto for the fiscal year ended March 31, 2013 (the “Form 10-K”), the
Company’s Quarterly Report on Form 10-Q and the exhibits thereto for the quarterly period ended June 30, 2013 (the “Form
10-Q”) and all subsequent periodic and current reports filed with the United States Securities and Exchange Commission (the
“SEC”) as publicly filed with and available at the website of the SEC which can be accessed at www.sec.gov, and hereby
represents that the Purchaser has been furnished by the Company during the course of the Offering with all information regarding
the Company, the terms and conditions of the Offering and any additional information that the Purchaser has requested or desired
to know, has been afforded the opportunity to ask questions of and receive answers from duly authorized officers or other representatives
of the Company concerning the Company and has been provided any such additional information by the
Company in writing to the full satisfaction of the Purchaser, if any;

 

(r)          The Purchaser represents to
the Company that any information which the undersigned has heretofore furnished or is furnishing herewith to the Company is complete
and accurate and may be relied upon by the Company in determining the availability of an exemption from registration under Federal
and state securities laws in connection with the offering of securities as described in the Memorandum;

 

(s)          The Purchaser has significant
prior investment experience, including investment in non-listed and unregistered securities. The Purchaser has a sufficient net
worth to sustain a loss of its entire investment in the Company in the event such a loss should occur. The Purchaser’s overall
commitment to investments which are not readily marketable is not excessive in view of the Purchaser’s net worth and financial
circumstances and the purchase of the Securities will not cause such commitment to become excessive. This investment is a suitable
one for the Purchaser;

 

(t)          The Purchaser is satisfied that
it has received adequate information with respect to all matters which it or its Advisors, if any, consider material to its decision
to make this investment;

 

(u)          The Purchaser acknowledges that
any and all estimates or forward-looking statements or projections included in the Memorandum were prepared by the Company in good
faith, but that the attainment of any such projections, estimates or forward-looking statements cannot be guaranteed, will not
be updated by the Company and should not be relied upon;

 

(v)          No oral or written representations
have been made, or oral or written information furnished, to the Purchaser or its Advisors, if any, in connection with the offering
of the Securities which are in any way inconsistent with the information contained in the Memorandum;

 

(w)          Within five (5) days after receipt
of a request from the Company, the Purchaser will provide such information and deliver such documents as may reasonably be necessary
to comply with any and all laws and ordinances to which the Company is subject;

 

    	8

    	 

    

 

(x)          THE SECURITIES OFFERED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF CERTAIN STATES AND ARE BEING OFFERED AND SOLD IN RELIANCE
ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY
AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION
THEREFROM. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE COMMISSION, ANY STATE SECURITIES COMMISSION OR ANY OTHER
REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY
OR ADEQUACY OF THE MEMORANDUM. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL;

 

(y)          In making an investment
decision, investors must rely on their own examination of Company and the terms of the Offering, including the merits and risks
involved. Investors should be aware that they will be required to bear the financial risks of this investment for an indefinite
period of time;

 

(z)          (For ERISA plans only)
The fiduciary of the ERISA plan (the “Plan”) represents that such fiduciary has been informed of and
understands the Company’s investment objectives, policies and strategies, and that the decision to invest “plan assets”
(as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA that require diversification of plan
assets and impose other fiduciary responsibilities. The Purchaser or Plan fiduciary (a) is responsible for the decision to invest
in the Company; (b) is independent of the Company and any of its affiliates; (c) is qualified to make such investment decision;
and (d) in making such decision, the Purchaser or Plan fiduciary has not relied on any advice or recommendation of the Company
or any of its affiliates; and

 

(aa)          The Purchaser has read in its
entirety the Memorandum and all exhibits and annexes thereto, including, but not limited to, all information relating to the Company,
and the Securities, and understands fully to its full satisfaction all information included in the Memorandum including, but not
limited to, the Section entitled “Risk Factors”.

 

(bb)          The
Purchaser represents that (i) the Purchaser was contacted regarding the sale of the Securities by the Company or the Placement
Agent (or another person whom the Purchaser believed to be an authorized agent or representative thereof) with whom the Purchaser
had a prior substantial pre-existing relationship and (ii) it did not learn of the offering of the Securities by means of any
form of general solicitation or general advertising, and in connection therewith, the Purchaser did not (A) receive or review
any advertisement, article, notice or other communication published in a newspaper or magazine or similar media or broadcast over
television or radio, whether closed circuit, or generally available; or (B) attend any seminar meeting or industry investor conference
whose attendees were invited by any general solicitation or general advertising.

 

    	9

    	 

    

 

(cc)          The Purchaser
consents to the placement of a legend on any certificate or other document evidencing the Securities and, when issued, the shares
of Common Stock issuable upon exercise of the Warrants (the “Warrant Shares”), that such securities have not been registered
under the Securities Act or any state securities or “blue sky” laws and setting forth or referring to the restrictions
on transferability and sale thereof contained in this Agreement. The Purchaser is aware that the Company will make a notation in
its appropriate records with respect to the restrictions on the transferability of such Securities. The legend to be placed on
each certificate shall be in form substantially similar to the following:

 

“THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY STATE
SECURITIES OR “BLUE SKY LAWS,” AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT
AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SUCH ACT, OR UNLESS THE COMPANY
HAS RECEIVED AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.”

 

(dd)          The Purchaser
acknowledges that if he or she is a Registered Representative of a Financial Industry Regulatory Authority (“FINRA”)
member firm, he or she must give such firm the notice required by the FINRA’s Rules of Fair Practice, receipt of which must
be acknowledged by such firm prior to an investment in the Securities.

 

(ee)          To effectuate
the terms and provisions hereof, the Purchaser hereby appoint the Placement Agent as its attorney-in-fact (and the Placement Agent
hereby accepts such appointment) for the purpose of carrying out the provisions of the Escrow Agreement by and between the Company,
the Placement Agent and _________________ (the “Escrow Agreement”) including, without limitation, taking any action
on behalf of, or at the instruction of, the Purchaser and executing any release notices required under the Escrow Agreement and
taking any action and executing any instrument that the Placement Agent may deem necessary or advisable (and lawful) to accomplish
the purposes hereof. All acts done under the foregoing authorization are hereby ratified and approved and neither the Placement
Agent nor any designee nor agent thereof shall be liable for any acts of commission or omission, for any error of judgment, for
any mistake of fact or law except for acts of gross negligence or willful misconduct. This power of attorney, being coupled with
an interest, is irrevocable while the Escrow Agreement remains in effect.

 

(ff)          The Purchaser
agrees not to issue any public statement with respect to the Offering, Purchaser’s investment or proposed investment in the
Company or the terms of any agreement or covenant between them and the Company without the Company’s prior written consent,
except such disclosures as may be required under applicable law.

 

    	10

    	 

    

 

(gg)          The Purchaser
understands, acknowledges and agrees with the Company that this subscription may be rejected, in whole or in part, by the Company,
in the sole and absolute discretion of the Company, at any time before any Closing notwithstanding prior receipt by the Purchaser
of notice of acceptance of the Purchaser’s subscription.

 

(hh)          The Purchaser
acknowledges that the information contained in the Offering Materials or otherwise made available to the Purchaser is confidential
and non-public and agrees that all such information shall be kept in confidence by the Purchaser and neither used by the Purchaser
for the Purchaser’s personal benefit (other than in connection with this subscription) nor disclosed to any third party for
any reason, notwithstanding that a Purchaser’s subscription may not be accepted by the Company; provided, however, that (a)
the Purchaser may disclose such information to its affiliates and advisors who may have a need for such information in connection
with providing advice to the Purchaser with respect to its investment in the Company so long as such affiliates and advisors have
an obligation of confidentiality, and (b) this obligation shall not apply to any such information that (i) is part of the public
knowledge or literature and readily accessible at the date hereof, (ii) becomes part of the public knowledge or literature and
readily accessible by publication (except as a result of a breach of this provision) or (iii) is received from third parties without
an obligation of confidentiality (except third parties who disclose such information in violation of any confidentiality agreements
or obligations, including, without limitation, any subscription or other similar agreement entered into with the Company).

 

(ii)          The Purchaser
understands that Rule 144 promulgated under the Act (“Rule 144”) requires, among other conditions, a minimum holding
period of six-months prior to the resale of securities acquired in a non-public offering without having to satisfy the registration
requirements under the Act. The Purchaser understands and hereby acknowledges that the Company is under no obligation to register
the Securities under the Act or any state securities or “blue sky” laws or to assist the Purchaser in obtaining an
exemption from various registration requirements, other than as set forth herein.

 

6.          Representations and Warranties
of the Company.

 

7.          Indemnification.
The Purchaser agrees to indemnify and hold harmless the Company, ___________ and each of
their respective officers, directors, managers, employees, agents, attorneys, control persons and affiliates from and against
all losses, liabilities, claims, damages, costs, fees and expenses whatsoever (including, but not limited to, any and all expenses
incurred in investigating, preparing or defending against any litigation commenced or threatened) based upon or arising out of
any actual or alleged false acknowledgment, representation or warranty, or misrepresentation or omission to state a material fact,
or breach by the Purchaser of any covenant or agreement made by the Purchaser herein or in any other document delivered in connection
with this Subscription Agreement or any other Transaction Document.

 

    	11

    	 

    

 

8.          Binding Effect. This Subscription
Agreement will survive the death or disability of the Purchaser and will be binding upon and inure to the benefit of the parties
and their heirs, executors, administrators, successors, legal representatives, and permitted assigns. If the Purchaser is more
than one person, the obligations of the Purchaser hereunder will be joint and several and the agreements, representations, warranties
and acknowledgments herein will be deemed to be made by and be binding upon each such person and such person’s heirs, executors,
administrators, successors, legal representatives and permitted assigns.

 

9.          Modification. This Subscription
Agreement will not be modified or waived except by an instrument in writing signed by the party against whom any such modification
or waiver is sought.

 

10.          Notices. Any notice or
other communication required or permitted to be given hereunder will be in writing and will be mailed by certified mail, return
receipt requested, or delivered by reputable overnight courier such as FedEx against receipt to the party to whom it is to be given
(a) if to the Company, at the address set forth in the Purchase Agreement or (b) if to the Purchaser, at the address set forth
on the signature page hereof (or, in either case, to such other address as the party will have furnished in writing in accordance
with the provisions of this Section 10). Any notice or other communication given by certified mail will be deemed given
at the time of certification thereof, except for a notice changing a party’s address which will be deemed given at the time
of receipt thereof. Any notice or other communication given by overnight courier will be deemed given at the time of delivery.

 

11.          Assignability. This Subscription
Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the Purchaser and the transfer
or assignment of any of the Securities will be made only in accordance with all applicable laws.

 

12.          Applicable
Law.  This Subscription Agreement will be governed by and construed under the laws of the State of New York as applied to
agreements among New York residents entered into and to be performed entirely within New York. The parties hereto (1) agree that
any legal suit, action or proceeding arising out of or relating to this Subscription Agreement
will be instituted exclusively in New York State Supreme Court, County of New York, or in the United States District Court for
the Southern District of New York, (2) waive any objection which the parties may have now or hereafter to the venue of any such
suit, action or proceeding, and (3) irrevocably consent to the jurisdiction of the New York State Supreme Court, County of New
York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding. Each
of the parties hereto further agrees to accept and acknowledge service of any and all process which may be served in any such
suit, action or proceeding in the New York State Supreme Court, County of New York, or in the United States District Court for
the Southern District of New York and agrees that service of process upon it mailed by certified mail to its address will be deemed
in every respect effective service of process upon it, in any such suit, action or proceeding. THE PARTIES HERETO AGREE, TO THE
EXTENT PERMITTED BY APPLICABLE LAW, TO WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON
OR ARISING OUT OF THIS SUBSCRIPTION AGREEMENT OR ANY DOCUMENT OR AGREEMENT CONTEMPLATED HEREBY.

 

    	12

    	 

    

 

13.          Blue Sky Qualification.
The purchase of Securities pursuant to this Subscription Agreement is expressly conditioned upon the exemption from qualification
of the offer and sale of the Securities from applicable federal and state securities laws.

 

14.          Use of Pronouns. All
pronouns and any variations thereof used herein will be deemed to refer to the masculine, feminine, neuter, singular or plural
as the identity of the person or persons referred to may require.

 

15.          Confidentiality. The
Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or about the Company not otherwise
properly in the public domain, was received in confidence. The Purchaser agrees not to divulge, communicate or disclose, except
as may be required by law or for the performance of this Subscription Agreement, or use to the detriment of the Company or for
the benefit of any other person or persons, or misuse in any way, any confidential information of the Company, including any trade
or business secrets of the Company and any business materials that are treated by the Company as confidential or proprietary, including,
without limitation, confidential information obtained by or given to the Company about or belonging to third parties.

 

16.          Miscellaneous.

 

(a)          This Subscription Agreement,
together with the other Transaction Documents, constitute the entire agreement between the Purchaser and the Company with respect
to the subject matter hereof and supersede all prior oral or written agreements and understandings, if any, relating to the subject
matter hereof. The terms and provisions of this Subscription Agreement may be waived, or consent for the departure therefrom granted,
only by a written document executed by the party entitled to the benefits of such terms or provisions.

 

(b)          Each of the Purchaser’s
and the Company’s representations and warranties made in this Subscription Agreement will survive the execution and delivery
hereof and delivery of the Securities.

 

(c)          Each of the parties hereto will
pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others engaged by such party) in
connection with this Subscription Agreement and the transactions contemplated hereby whether or not the transactions contemplated
hereby are consummated.

 

(d)          This Subscription Agreement
may be executed in one or more counterparts each of which will be deemed an original, but all of which will together constitute
one and the same instrument.

 

(e)          Each provision of this
Subscription Agreement will be considered separable and, if for any reason any provision or provisions hereof are determined to
be invalid or contrary to applicable law, such invalidity or illegality will not impair the operation of or affect the remaining
portions of this Subscription Agreement.

 

    	13

    	 

    

 

(f)          Paragraph titles are for descriptive
purposes only and will not control or alter the meaning of this Subscription Agreement as set forth in the text.

 

17.          Signature
Page. It is hereby agreed by the parties hereto that the execution by the Purchaser of this Subscription Agreement,
in the place set forth hereinbelow, will be deemed and constitute the agreement by the Purchaser to be bound by all of the terms
and conditions hereof as well as by the Unit Purchase Agreement and each of the other Transaction Documents, and will be deemed
and constitute the execution by the Purchaser of all such Transaction Documents without requiring the Purchaser’s separate
signature on any of such Transaction Documents.

 

 

 

 

 

[Remainder of page intentionally left
blank.]

 

 

 

 

 

 

 

 

 

 

 

    	14

    	 

    

 

ANTI-MONEY LAUNDERING REQUIREMENTS

 

 

 

 

 

	
        The USA PATRIOT Act

         

         

         
	What is money laundering?	How big is the problem and why is it important?
	
         

         

        The USA PATRIOT Act is designed to detect, deter, and punish
        terrorists in the United States and abroad. The Act imposes new anti-money laundering requirements on brokerage firms and financial
        institutions. Since April 24, 2002 all brokerage firms have been required to have new, comprehensive anti-money laundering programs.

         

        To help you understand theses efforts, we want to provide you
        with some information about money laundering and our steps to implement the USA PATRIOT Act.

         
	
         

         

        Money laundering is the process of disguising illegally obtained
        money so that the funds appear to come from legitimate sources or activities. Money laundering occurs in connection with a wide
        variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism.

         
	
         

         

        The use of the U.S. financial system by criminals to facilitate
        terrorism or other crimes could well taint our financial markets. According to the U.S. State Department, one recent estimate puts
        the amount of worldwide money laundering activity at $1 trillion a year.

         

 

 

	What are we required to do to eliminate money laundering?
	
         

         

        Under new rules required by the USA PATRIOT Act, our anti-money
        laundering program must designate a special compliance officer, set up employee training, conduct independent audits, and establish
        policies and procedures to detect and report suspicious transaction and ensure compliance with the new laws.

         
	
         

         

        As part of our required program, we may ask you to provide various
        identification documents or other information. Until you provide the information or documents we need, we may not be able to effect
        any transactions for you.

         

 

 

    	15

    	 

    

 

AETHLON MEDICAL,
INC.

SIGNATURE PAGE TO

SUBSCRIPTION AGREEMENT

 

Purchaser hereby elects to purchase
a total of ______Unit(s) at a purchase price of $12,500 per Unit (NOTE: to be completed by the Purchaser).

 

Date (NOTE: To be completed by the Purchaser):
__________________, 2013

 

If the
Purchaser is an INDIVIDUAL, and if purchased as JOINT TENANTS, as TENANTS IN COMMON, or as COMMUNITY PROPERTY:

  

	____________________________	______________________________
	Print Name(s)	Social Security Number(s)
	 	 
	___________________________	______________________________
	Signature(s) of Purchaser(s)	Signature
	 	 
	____________________________	______________________________
	Date	Address

 

If the
Purchaser is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY or TRUST:

 

	____________________________	______________________________
	Name of Partnership,	Federal Taxpayer
	Corporation, Limited 	Identification Number
	Liability Company or Trust	 
	 	 
	By:_________________________	______________________________
	      Name:	State of Organization
	      Title:	 
	 	 
	____________________________	______________________________
	Date	Address

 

AGREED AND ACCEPTED:

 

AETHLON MEDICAL, INC.

  

	By:__________________________	_________________
	      Name:	Date
	      Title:	 

 

    	16

    	 

    

 

AETHLON MEDICAL, INC.

ACCREDITED INVESTOR CERTIFICATION

 

For Individual Investors Only

(All individual investors must INITIAL
where appropriate. Where there are joint investors both parties must INITIAL):

 

Initial
_______     I certify that I have a “net worth” of at least $1 million either individually or through aggregating
my individual holdings and those in which I have a joint, community property or other similar shared ownership interest with my
spouse. For purposes of calculating net worth under this paragraph, (i) the primary residence shall not be included as an asset,
(ii) to the extent that the indebtedness that is secured by the primary residence is in excess of the fair market value of the
primary residence, the excess amount shall be included as a liability, and (iii) if the amount of outstanding indebtedness that
is secured by the primary residence exceeds the amount outstanding 60 days prior to the execution of this Subscription Agreement,
other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability.

 

Initial
_______     I certify that I have had an annual gross income for the past two years of at least $200,000
(or $300,000 jointly with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current
year.

 

 

For Non-Individual
Investors

(all Non-Individual
Investors must INITIAL where appropriate):

 

Initial
_______    The undersigned certifies that it is a partnership, corporation, limited liability company or business trust that
is 100% owned by persons who meet either of the criteria for Individual Investors, above.

 

Initial
_______    The undersigned certifies that it is a partnership, corporation, limited liability company or business trust that
has total assets of at least $5 million and was not formed for the purpose of investing in Company.

 

Initial
_______    The undersigned certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary
(as defined in ERISA §3(21)) that is a bank, savings and loan association, insurance company or registered investment adviser.

 

Initial
_______    The undersigned certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the date
of the Subscription Agreement.

 

Initial
_______    The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely
by persons who meet either of the criteria for Individual Investors, above.

 

Initial
_______    The undersigned certifies that it is a U.S. bank, U.S. savings and loan association or other
similar U.S. institution acting in its individual or fiduciary capacity.

 

Initial
_______    The undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange
Act of 1934.

 

Initial
_______    The undersigned certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with
total assets exceeding $5,000,000 and not formed for the specific purpose of investing in Company.

 

Initial
_______    The undersigned certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific
purpose of investing in Company, and whose purchase is directed by a person with such knowledge and experience in financial and
business matters that he is capable of evaluating the merits and risks of the prospective investment.

 

Initial
_______    The undersigned certifies that it is a plan established and maintained by a state or its political subdivisions,
or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000.

 

Initial
_______    The undersigned certifies that it is an insurance company as defined in §2(a)(13) of the Securities Act of
1933, as amended, or a registered investment company.

 

    	17

    	 

    

 

AETHLON MEDICAL, INC.

Purchaser
Questionnaire

(Must be completed by Purchaser)

 

 

Section A - Individual Purchaser
Information

 

Purchaser Name(s): ________________________________________________________________________

 

Individual executing Profile or Trustee: _______________________________________________________________________

 

Social Security Numbers / Federal I.D. Number: ________________________________________________________________________

 

Date of Birth: _________________ Marital Status: _________________

 

Joint Party Date of Birth:_________________

Investment Experience (Years): ___________

 

Annual Income: _________________ 

Liquid Net Worth:____________

 

Net Worth: ________________

 

Investment Objectives (circle
one or more):     Long Term Capital Appreciation, Short Term Trading, Businessman’s Risk, Income, Safety of Principal,
Tax Exempt Income or other

 

Home Street Address: ________________________________________________________________________

 

Home City, State & Zip Code: ________________________________________________________________________

 

Home Phone: ________________________ Home Fax: _____________________

 

Home Email: _______________________________

 

Employer: ________________________________________________________________________

 

Employer Street Address: ________________________________________________________________________

 

Employer City, State & Zip Code: ________________________________________________________________________

 

Bus. Phone: __________________________ Bus. Fax: _______________________

 

Bus. Email: ________________________________

 

Type of Business: ________________________________________________________________________

 

___________ Account
Executive / Outside Broker/Dealer: _______________________________________________________

 

Please check if you are a FINRA
member or affiliate of a FINRA member firm: _______

 

    	18

    	 

    

 

AETHLON
MEDICAL, INC.

Purchaser
Questionnaire

(Must be completed by Purchaser)

 

 

Section B – Entity Purchaser
Information

 

Purchaser Name(s): ________________________________________________________________________

 

Authorized Individual executing Profile or Trustee: _______________________________________________________________________

 

Social Security Numbers / Federal I.D. Number: ________________________________________________________________________

 

Investment Experience (Years): ___________

 

Annual Income: _______________ 

 

Net Worth: ________________

 

Was the Entity formed for the specific purpose of purchasing
the Common Stock and Warrants? [  ] Yes [  ] No

 

Principal Purpose (Trust)______________________________________

 

Type of Business: ________________________________________________________

 

Investment Objectives (circle
one or more):     Long Term Capital Appreciation, Short Term Trading, Businessman’s Risk, Income, Safety of Principal,
Tax Exempt Income or other

 

Street Address: ________________________________________________________________________

 

City, State & Zip Code: ________________________________________________________________________

 

Phone: ________________________ Fax: ________________________

 

Email: __________________________

 

___________ Account
Executive / Outside Broker/Dealer: 

 

_______________________________________________________

 

Please check if you are a FINRA
member or affiliate of a FINRA member firm: _______

 

 

    	19

    	 

    

 

Section C – Form of Payment
– Check or Wire Transfer

 

 

____ Check payable to “_________________,
AS ESCROW AGENT FOR AETHLON MEDICAL, INC.

 

____ Wire funds from my outside account
according to the “To subscribe for Units of Common Stock and Warrants to Purchase
Shares of Common Stock in the private offering of AETHLON MEDICAL, INC.” 

 

____ Wire funds from my _________________
Account – See following page

 

____ The funds
for this investment are rolled over, tax deferred from ____________________ within the Allowed 60-day window

 

 

Section D – Purchaser Instructions
for Payments of any Dividends

 

[  ] Please
make any dividend and any other payment checks pursuant to the Units to “_________________ c/f [Insert Client
Name]” and deliver such checks to _________________ so
that they may deposit them into my _________________ brokerage account

 

[  ] Please make out any dividend and any
other payment checks pursuant to the Units in the registered name of the Purchaser set forth in the signature page to
the Subscription Agreement for the Units and mail such checks to me at the address specified in such signature page

 

 

Section E – Securities Delivery
Instructions (check one)

 

____ Please deliver my securities
to _________________ for deposit into my brokerage account.

 

____ Please deliver my securities to the address listed in the
above Purchaser Questionnaire.

 

____ Please deliver my securities to the below address:

_________________

_________________

_________________

_________________

 

Purchaser Signature(s): _______________________________________Date:_______________

 

    	20

    	 

    

 

Wire Transfer Authorization

 

	TO:	OPERATIONS MANAGER
	 	_________________
	 	 
	RE:	Client Wire Transfer Authorization
	 	AETHLON MEDICAL, INC.
	 	 
	DATE:	________________

 

 

 

This
memorandum authorizes the transfer of the following listed funds from my _________________ Brokerage
Account as follows:

 

_________________ Brokerage Account #    ______________________

 

Wire Amount     $______________________

 

_________________

_________________

_________________

 

ABA Number: 

For
Credit to _________________, as Escrow Agent for 

Aethlon Medical,
Inc.

Account No.: 

 

 

REFERENCE:

 

PURCHASER'S LEGAL NAME     ______________________________________________________

 

TAX ID NUMBER    ______________________________________________________

 

PURCHASER'S ADDRESS    ______________________________________________________

 

FBO: ________________________________________________

 

 

Signature:________________________________________________

 

Signature:________________________________________________

       (Joint Signature)

 

 

    	21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]